Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
Overview
- Phase
- Phase 2
- Intervention
- Irinotecan
- Conditions
- Ovarian Cancer
- Sponsor
- NYU Langone Health
- Enrollment
- 29
- Locations
- 2
- Primary Endpoint
- Progression Free Survival (PFS) Rate at 6 Months
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of the study is to evaluate the efficacy and toxicity of irinotecan in the treatment of women with recurrent epithelial ovarian cancer or primary peritoneal cancer when combined with bevacizumab.
Detailed Description
Accumulating data suggests that angiogenesis plays a critical role in the formation and development of a number of solid tumors including ovarian cancer. For women with ovarian cancer, a direct relationship between vascular endothelial growth factor (VEGF) expression and tumor vascularity has been documented. In vivo and in vitro data has demonstrated that increased angiogenesis and microvessel density are negative prognostic factors for women with ovarian cancer. These observations have fueled interest in incorporating anti-angiogenic agents into ovarian cancer treatment regimens. Several phase II trials of irinotecan in patients with epithelial ovarian cancer showed that the drug had efficacy in both chemotherapy-naïve patients and in those who had been previously treated with standard therapies, including platinum-based compounds, radiation, or both. Combination of bevacizumab, an antibody against VEGF, and irinotecan was studied in colorectal cancer and malignant brain neoplasms. In these trials, the combination was shown to be safe and effective. The purpose of this study is to evaluate the efficacy and toxicity of irinotecan in the treatment of women with recurrent epithelial ovarian cancer or primary peritoneal cancer when combined with bevacizumab. In this phase II open-label study patients will be treated with bevacizumab 15 mg/kg and irinotecan 175mg/m\^2 every 3 weeks. Patients will undergo pre-treatment evaluation within 4 weeks of enrolling into the study. Clinical and laboratory evaluation will be performed every 3 weeks. Imaging studies and CA-125 measurements will be used to assess response to treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women with recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma
- •Patient should have measurable or evaluable disease as defined by the following.
- •Measurable disease: At least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must be ≥ 20 mm when measured by conventional techniques, including palpation, plain x-ray, CT and MRI, or ≥ 10 mm when measured by spiral CT.
- •Evaluable (nonmeasurable) disease: Patients who do not meet measurable criteria will be eligible having known disease with CA125 levels \>50 U/mL on two occasions at least one week apart. They will be considered for CA125 response criteria.
- •Any number of prior chemotherapy regimens
- •Any number of prior bevacizumab-containing regimens
- •No chemotherapy within the last 2 weeks prior to initiating this study.
- •Karnofsky Performance status score ≥ 60%.
- •Patients must have a life expectancy ≥ 12 weeks.
- •Patients must be at least 18 years of age.
Exclusion Criteria
- •Inability to comply with study and/or follow-up procedures
- •Life expectancy of less than 12 weeks
- •Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study
- •Active malignancy, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within last five years
- •Bevacizumab-Specific Exclusions
- •Inadequately controlled hypertension (defined as systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 100 mmHg)
- •Prior history of hypertensive crisis or hypertensive encephalopathy
- •New York Heart Association (NYHA) Grade II or greater congestive heart failure
- •History of myocardial infarction or unstable angina within 6 months prior to Day 1
- •History of stroke or transient ischemic attack within 6 months prior to Day 1 Known central nervous system disease, except for treated brain metastasis
Arms & Interventions
Irinotecan with Bevacizumab
Irinotecan is administered every 3 weeks at a dose of 175 mg/m\^2, bevacizumab is administered at 15 mg/kg every 3 weeks. Irinotecan is administered before bevacizumab. Patients will continue on therapy until evidence of disease progression, or until development of adverse events that prevent further treatment, or if the patients wishes to discontinue therapy.
Intervention: Irinotecan
Irinotecan with Bevacizumab
Irinotecan is administered every 3 weeks at a dose of 175 mg/m\^2, bevacizumab is administered at 15 mg/kg every 3 weeks. Irinotecan is administered before bevacizumab. Patients will continue on therapy until evidence of disease progression, or until development of adverse events that prevent further treatment, or if the patients wishes to discontinue therapy.
Intervention: Bevacizumab
Outcomes
Primary Outcomes
Progression Free Survival (PFS) Rate at 6 Months
Time Frame: 6 months from the start of treatment
The PFS rate at 6 months is the percentage of patients that experience a PFS event during the first 6 months in the study. The PFS is defined as the time from date of first dose of study medication to the date of first documented disease progression, or death from any cause, whichever is first. Patients who die without a reported prior progression will be considered to have progressed on the day of their death. Progression is evaluated by Response and Evaluation Criteria in Solid Tumor (RECIST) 1.0 or CA125 criteria if no measurable disease as doubling of CA125 levels from either the upper limit of normal or the nadir CA125 level.
Secondary Outcomes
- Median Overall Survival(up to 3 years)
- Number of Patients Who Experienced Grade 3 and Higher Toxicities(up to 3 years)
- Overall Response Rate (ORR)(up to 3 years)
- Median Progression Free Survival(up to 3 years)